Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
CTMXthis companyCytomX Therapeutics, Inc.	$2.12	-28.4×	5.93×	7.71×	-36.76×	-283.4%	100.0%	-29.3%	-22.8%	-17.5%	-20.5%	-12.9%	0.04×	0.53×	0×	3.09×	0.0%	1	1.34	2	C
CLDXCelldex Therapeutics, Inc.	$30.98	-6.96×	3.43×	1,204.09×	-6.97×	-99.2%	100.0%	-19160.0%	-17253.3%	-49.1%	-53.9%	-11.8%	0×	0.1×	0×	10.49×	0.0%	2	16.42	2	C
MGNXMacroGenics, Inc.	$2.47	-1.36×	1.83×	0.68×	-2.54×	-2714.5%	71.1%	-48.7%	-49.9%	-134.2%	-33.0%	-81.6%	1.92×	-0.83×	-8.56×	5.1×	0.0%	1	-4.43	1	D+
NRIXNurix Therapeutics, Inc.	$16.09	-5.54×	2.72×	17.45×	-5.2×	-213.0%	77.5%	-340.2%	-314.9%	-49.1%	-47.3%	-18.0%	0.1×	0.78×	0×	7.02×	0.0%	7	9.1	4	A-
PYXSPyxis Oncology, Inc.	$1.75	-0.9×	1.34×	5.16×	-1.01×	-0.4%	82.8%	-609.2%	-574.5%	-149.1%	-117.1%	-88.9%	0.35×	-0.04×	0×	3.41×	0.0%	2	-15.92	1	C-
STROSutro Biopharma, Inc.	$10.27	-0.51×	-0.74×	0.96×	-0.38×	-557.0%	92.9%	-102.4%	-186.5%	144.3%	-98.5%	-182.0%	-0.12×	0.29×	-2.75×	2.01×	0.0%	3	-8.69	2	C
Peer median	—	-1.36×	1.83×	5.16×	-2.54×	-213.0%	82.8%	-340.2%	-314.9%	-49.1%	-53.9%	-81.6%	0.1×	0.1×	0×	5.1×	0.0%	2	-4.43	2	—